Sonnet biotherapeutics provides fiscal year 2023 first quarter business and earnings update

Data announced from two clinical trials of son-1010 in both healthy volunteers and patients with advanced solid tumors entered into collaboration with janssen biotech for the evaluation of three sonnet pipeline compounds successfully completed two ind-enabling toxicology studies with son-1210 in non-human primate princeton, nj / accesswire / february 13, 2023 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) ("sonnet" or the "company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended december 31, 2022 and provided a business update. "this was a productive quarter for sonnet and one of which we are particularly proud.
SONN Ratings Summary
SONN Quant Ranking